Innovation towards improved infertility treatments
We identified a drug that activate eggs in infertile women

Market drivers
- Premature ovarian failure
- Aging population
- Increased awareness
- Reimbursement and insurances
- Strong reproductive instinct

Assets
- Growing marked
- Strong scientific team
- Fertility consultants
- Experienced Business developers

Technology Description
Our invention is based in specific data sets that analysed global expression of genes during the earliest stages in egg maturation. We identified a novel potential target and are currently developing a new formulation to enhance activation of dormant eggs in the ovary. The target identified is highly present in the early egg cells and through proof of concept in vitro and ex vivo studies, we showed that pharmacological treatment could promote activation of the earliest egg cells in aged mice and POI patients, respectively.

We are working towards maturing the technology in a spin-out company.

Intellectual Property Rights

Current State
In vitro and ex vivo proof-of-concept has been established. The project is, at this stage, funded by soft funding.

In vivo confirmation, CMC and toxicity studies initiated. Phase I/IIa clinical trial is expected in 2022/2023.

Business opportunity and Call to action
The global fertilization market is projected to reach $27 Billion by 2022 (Grand View Research, Inc)

We are looking to develop collaborations and partnerships for registration studies with companies that has experience in fertility treatment.

Contact information
Morten Holmager
Business Development Manager
Mobile: +45 9350 8718
E-mail: holmager@au.dk

AARHUS UNIVERSITY

In vitro and ex vivo proof of concept
Drug formulation
FDA approval

Outsourced 2020-21
Clinical trial 2022-2023

Team
- Management
  - Associate Professor Karin Lykke-Hartmann Scientific lead
  - Per Horn, PhD Business strategy
- Postdoc Mahboobe Amoushahi, Reproductive models
- Technician Anders Heuck Single cell techniques
- Professor MD Erik Ernst Fertility treatment

Ex vivo proof of concept

Claudia Ancher, Management Assistant